Does Dr. EHSAN RAHIMY have financial conflicts of interest?

Dr. EHSAN RAHIMY (MD) has received a total of $1,246,826 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $1,230,313 in personal promotional payouts (consulting, meals, travel) and $16,513 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. EHSAN RAHIMY?

According to CMS Open Payments data, Dr. EHSAN RAHIMY received funding from REGENERON HEALTHCARE SOLUTIONS ($575,364), APELLIS PHARMACEUTICALS ($316,037), and GENENTECH USA ($79,540).

Does Dr. EHSAN RAHIMY receive research grants or speaking fees?

Dr. EHSAN RAHIMY has received $1,230,313 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $16,513 in clinical research grants.

DR. EHSAN RAHIMY

MDReal-Time Hydrated

Specialty: Ophthalmology, Retina Specialist

Practice Location: STANFORD, CA 94305

NPI Number: 1255573606

LIFETIME INDUSTRY VALUE

$1,246,826

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. RAHIMY is a verified Ophthalmology, Retina Specialist practitioner based in STANFORD, CA.

Between 2021 and 2025, Dr. RAHIMY had an overall industry promotional and research financial footprint of $1,246,826 as recorded in the federal CMS Open Payments database.

$1,230,313 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$16,513 was allocated to sponsored clinical trials and medical research activities.

Dr. RAHIMY's primary funding source is REGENERON HEALTHCARE SOLUTIONS, which accounts for $575,364 (representing 46.1% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

REGENERON HEALTHCARE SOLUTIONS

Rank 1

$575,364

46.1%

APELLIS PHARMACEUTICALS

Rank 2

$316,037

25.3%

GENENTECH USA

Rank 3

$79,540

6.4%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.